Tissue Disposition of 5-o-Carboranyluracil-A Novel Agent for the Boron Neutron Capture Therapy of Prostate Cancer

The carboranyl nucleotides β-d-5-o-carboranyl-2′-deoxyuridine (d-CDU), 1-(β-l-arabinosyl)-5-o-carboranyluracil (d-ribo-CU) and the nucleotide base 5-o-carboranyluracil (CU), were developed as sensitizers for boron neutron capture therapy (BNCT). A structure activity study was initiated to determine...

Full description

Saved in:
Bibliographic Details
Published in:Nucleosides, nucleotides & nucleic acids nucleotides & nucleic acids, 2004-01, Vol.23 (1-2), p.291-306
Main Authors: Schinazi, Raymond F., Hurwitz, Selwyn J., Liberman, Irina, Glazkova, Yuliya, Mourier, Nicolas S., Olson, Jeffrey, Keane, Thomas
Format: Article
Language:English
Subjects:
Animals
Boron Compounds - pharmacokinetics
Boron Neutron Capture Therapy
Humans
Male
Mice
Mice, Nude
Nucleosides
Organ Specificity
Prostate - metabolism
Prostate tumors
Prostatic Neoplasms - metabolism
Prostatic Neoplasms - radiotherapy
Time Factors
Uracil - analogs & derivatives
Uracil - chemistry
Uracil - pharmacokinetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The carboranyl nucleotides β-d-5-o-carboranyl-2′-deoxyuridine (d-CDU), 1-(β-l-arabinosyl)-5-o-carboranyluracil (d-ribo-CU) and the nucleotide base 5-o-carboranyluracil (CU), were developed as sensitizers for boron neutron capture therapy (BNCT). A structure activity study was initiated to determine the agent most suitable for targeting prostate tumors. Cellular accumulation studies were performed using LNCaP human prostate tumor cells, and the respective tumor disposition profiles were investigated in male nude mice bearing LNCaP and 9479 human prostate tumor xenografts in their flanks. d-CDU achieved high cellular concentrations in LNCaP cells and up to 2.5% of the total cellular compound was recovered in the 5′-monophosphorylated form. In vivo concentrations of d-CDU were similar in LNCaP and 9479 tumor xenografts. Studies in 9479 xenografted bearing mice indicated that increasing the number of hydroxyl groups in the sugar moeity of the carboranyl nucleosides corresponded with an increased rate and extent of renal elimination, shorter serum half-lives and an increased tissue specificity. Tumor/normal prostate ratios were greatest with the nucleoside base CU. These studies indicate that similar nucleoside analogues and bases may have different tissue affinities and retention properties, which should be considered when selecting agents for sensitizing specific tumors for eventual BNCT treatment. CU was found to be the most suitable compound for further development to treat prostate cancer. † In honor and celebration of the 70th birthday of Professor Leroy B. Townsend.
ISSN:1525-7770
1532-2335
DOI:10.1081/NCN-120027836